Press release
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients
Anti-tumor activity following blockade of PVRIG with COM701 when added to nivolumab is supported by potent tumor microenvironment (TME) immune activation in
About this update from Compugen Ltd.
[{"type":"text","content":"Anti-tumor activity following blockade of PVRIG with COM701 when added to nivolumab is supported by potent tumor microenvironment (TME) immune activation in MSS-CRC patients typically not responding to approved checkpoint inhibitorsPVRIG unique dominant expression on early differentiated stem-like memory T cells in tertiary lymphoid structures, suggests its role in inhibiting T cell expansion in tumorsFindings support the differentiation of PVRIG from other immune checkpointsManagement to discuss findings presented at SITC as part of the Q3 earnings call on Monday, November 14, 2022, at 8:30 am ETHOLON, Israel, Nov. 7, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today, publication of the abstract on data demonstrating that anti-tumor activity following blockade of PVRIG with COM701 is supported by potent tumor microenvironment (TME) immune activation in MSS-CRC patients. The data will be presented as an oral presentation by Eran Ophir, Ph.D., SVP, Research and Drug Discovery, Compugen, at the annual meeting of the Society for Immunotherapy of Cancer (SITC) on Friday November 11, 2022 in Boston, MA. In addition to the data in the abstract, the Friday oral presentation will include new translational data from a number of platinum resistant ovarian cancer patients treated with COM701 monotherapy and from the fully enrolled MSS-CRC COM701 and nivolumab cohort.\n\"I believe the data we will present at SITC support the potential of PVRIG to open new possibilities in cancer immunotherapy,\" said Dr. Eran Ophir. \"The translational data are exciting because they support the anti-tumor activity we have shown with COM701 in combination with nivolumab in patients with MSS-CRC typically not responsive to approved checkpoint inhibitors. Historically nivolumab monotherapy has shown limited response in this patient population. The data to be presented at SITC show that blocking PVRIG and PD-1 with COM701 and nivolumab resulted in increased clonal expansion and T cell infiltration in the two MSS-CRC patients with partial responses. Peripheral immune modulation was also seen with COM701 alone in a platinum resistant ovarian cancer patient with a partial response.\"\nDr. Ophir further elaborated, \"The differentiated attributes of PVRIG...